Anaphylaxis upon switching lipid-containing amphotericin B formulations.
Kauffman
C A
CA
Department of Internal Medicine, Veterans Affairs Medical Center, Ann Arbor, Michigan, USA.
Wiseman
S W
SW
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000707:Anaphylaxis / Q000139:chemically induced*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003047:Coccidioidomycosis / Q000188:drug therapy; D004338:Drug Combinations; D006801:Humans; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D008055:Lipids / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D016921:Meningitis, Fungal / Q000188:drug therapy; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000627:therapeutic use; D010715:Phosphatidylglycerols / Q000008:administration & dosage / Q000627:therapeutic use
D000935:Antifungal Agents; D004338:Drug Combinations; D008055:Lipids; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B